Working… Menu
Trial record 1 of 1 for:    Saved Studies
Previous Study | Return to List | Next Study

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00911560
Recruitment Status : Recruiting
First Posted : June 2, 2009
Last Update Posted : July 29, 2020
Y-mAbs Therapeutics, Inc
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center